Loading..

Veracyte, Inc. (VCYT) Report Analysis

Corporate Events

Positive

Veracyte, Inc. Shows Strong Performance of Vera...

2022-06-20 12:15:00

Veracyte, Inc. announced that findings from a new meta-analysis provide real-world evidence that the Afirma Genomic Sequencing Classifier can ...

Neutral

Veracyte, Inc. Presents at ENDO 2022 Annual Con...

2022-06-20 12:15:00

Veracyte, Inc. Presents at ENDO 2022 Annual Conference, Jun-11-2022 . Venue: Atlanta, Georgia, United States.

Positive

Veracyte, Inc. Announces the Publication of Dat...

2022-06-03 12:30:00

Veracyte, Inc. announced the publication of data reinforcing the clinical utility of the Decipher Prostate genomic classifier for helping to g...

Positive

Veracyte, Inc. Announces that New Data Show Imm...

2022-05-31 20:20:00

Veracyte, Inc. announced that new data published online in The Lancet Oncology suggest that the company's Immunoscore Immune Checkpoint (IC) a...

Neutral

Veracyte, Inc. Presents at Goldman Sachs 43rd A...

2022-05-27 00:00:00

Veracyte, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 02:40 PM. Venue: Terranea Resort, Rancho Palos ...

Positive

Veracyte, Inc. Announces New Data to be Present...

2022-05-26 21:05:00

Veracyte, Inc. announced new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) assay to ...

Neutral

Veracyte, Inc. Presents at William Blair’s 42nd...

2022-05-26 12:15:00

Veracyte, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 01:40 PM. Venue: Loews Chicago Hotel, Chicago...

Positive

Veracyte, Inc. Announces New Data Reinforcing P...

2022-05-16 20:17:00

Veracyte, Inc. announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smok...

Neutral

Veracyte, Inc. Presents at American Association...

2022-05-12 18:39:00

Veracyte, Inc. Presents at American Association of Clinical Endocrinology (AACE) Annual Meeting, May-12-2022 . Venue: San Diego, United States...

Neutral

Veracyte, Inc. Presents at The 2022 ASCO Annual...

2022-05-12 12:30:00

Veracyte, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-06-2022 01:15 PM. Venue: McCormick Place, Chicago, Illinois, United States. Speak...

Positive

Veracyte, Inc. Revises Revenue Guidance for the...

2022-05-03 20:05:00

Veracyte, Inc. revised revenue guidance for the full year 2022. The company is currently projecting full year 2022 total revenue of $265 milli...

Neutral

Veracyte, Inc. Presents at American Urological ...

2022-04-28 20:15:00

Veracyte, Inc. Presents at American Urological Association, May-13-2022 through May-16-2022. Venue: New Orleans, Louisiana, United States. Pre...

Neutral

Veracyte, Inc., Annual General Meeting, Jun 15, 2022

2022-04-26 20:15:00

Veracyte, Inc., Annual General Meeting, Jun 15, 2022.

Neutral

Veracyte, Inc. - Shareholder/Analyst Call

2022-04-26 20:15:00

Annual General Meeting

Neutral

Veracyte, Inc. Presents at American Thoracic So...

2022-04-26 20:05:00

Veracyte, Inc. Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022. Venue: San Francicso, Cal...

Neutral

Veracyte, Inc., Q1 2022 Earnings Call, May 03, 2022

2022-04-19 12:15:00

Veracyte, Inc., Q1 2022 Earnings Call, May 03, 2022

Neutral

Veracyte, Inc. to Report Q1, 2022 Results on Ma...

2022-04-19 12:15:00

Veracyte, Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022

Neutral

American Urological Association, Inc, American ...

2022-03-29 00:00:00

American Urological Association, Inc, American Urological Association, May 13, 2022 through May 16, 2022. Venue: New Orleans, Louisiana, Unite...

Neutral

Endocrine Society, ENDO 2022 Annual Conference,...

2022-02-28 18:25:00

Endocrine Society, ENDO 2022 Annual Conference, Jun 11, 2022 through Jun 14, 2022. Venue: Atlanta, Georgia, United States.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43...

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Reso...

Positive

Veracyte Announces New Data to be Presented at ...

2022-01-31 13:25:00

Veracyte, Inc. announced that six abstracts highlighting new data for the company’s Decipher urologic cancer tests will be presented at the 20...

Neutral

William Blair & Company, L.L.C., William Blair’...

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chi...

Positive

Veracyte Announces Publication of Data Demonstr...

2021-12-14 21:05:00

Veracyte, Inc. announced the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnost...

Neutral

American Society Of Clinical Oncology, Inc., th...

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago,...

Positive

Veracyte Announces New Data on Immuno-Oncology ...

2021-11-13 12:00:00

Veracyte, Inc. announced that new data from three posters were presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeti...

Neutral

American Thoracic Society, Inc, American Thorac...

2021-11-13 09:53:00

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francic...

Positive

Veracyte, Inc. Revises Earnings Guidance for th...

2021-11-09 21:05:00

Veracyte, Inc. revised earnings guidance for the year of 2021, for the year, the company is updating its 2021 annual total revenue guidance to...

Positive

Veracyte, Inc. Announces Immunoscore Colon Canc...

2021-11-05 12:15:00

Veracyte, Inc. announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO1 Clinical Practice Guidelines ...

Positive

Veracyte, Inc. Announces the Publication of New...

2021-11-03 12:15:00

Veracyte, Inc. announced the publication of new long-term clinical utility data showing that the company’s Afirma Genomic Sequencing Classifie...

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global...

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, Unit...

Positive

Veracyte, Inc. Announces New Data Demonstrate C...

2021-10-26 13:25:00

Veracyte, Inc. announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the tim...

Positive

Veracyte, Inc. Announces That New Data Being Pr...

2021-10-25 14:30:00

Veracyte, Inc. announced that new data being presented at the American Society for Radiation Oncology 2021 Annual Meeting suggest the company’...

Positive

New Data to be Presented at ASTRO 2021 Further ...

2021-10-14 12:35:00

Veracyte, Inc. announced that new data further validating the clinical utility of the company’s Decipher Prostate genomic test will be present...

Positive

Veracyte, Inc. Announces the Publication of New...

2021-10-13 12:55:00

Veracyte, Inc. announced the publication of new data demonstrating that the company’s Decipher Bladder genomic classifier accurately identifie...

Neutral

Veracyte, Inc. to Report Q3, 2021 Results on No...

2021-10-12 20:05:00

Veracyte, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Neutral

Veracyte, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-10-12 20:05:00

Veracyte, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Positive

New Clinical Utility Data Confirm Veracyte’s En...

2021-10-11 20:41:00

Veracyte, Inc. announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic ...

Positive

Veracyte, Inc. Announces New Expanded Data at C...

2021-10-11 12:15:00

Veracyte, Inc. announced that new expanded clinical validation data reinforce the ability of the company’s noninvasive Percepta Nasal Swab tes...

Positive

Veracyte, Inc Announces New NCCN Guidelines Uni...

2021-09-14 20:05:00

Veracyte, Inc. announced that its Decipher® Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer N...

Negative

Veracyte, Inc. Announces Appointment of Joshua ...

2021-09-01 12:35:00

Veracyte, Inc. announced that it has appointed Joshua Klopper, M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recogni...

Neutral

Veracyte, Inc. Presents at Morgan Stanley 19th ...

2021-08-31 12:15:00

Veracyte, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 03:30 PM. Venue: New Windsor, United States. S...

Neutral

Veracyte, Inc. has closed its Shelf Registratio...

2021-08-04 00:00:00

Veracyte, Inc. has closed its Shelf Registration dated August 04, 2021 in the amount of $147.088842 million. Security Name: Common Stock S...

Positive

Veracyte, Inc. (NasdaqGM:VCYT) completed the ac...

2021-08-02 00:00:00

Veracyte, Inc. (NasdaqGM:VCYT) entered into a memorandum of understanding to acquire HalioDx SAS from M.I.3. SA, PSIM fund managed by Bpifranc...

Neutral

Veracyte, Inc. Presents at Lake Street Capital ...

2021-07-31 04:07:00

Veracyte, Inc. Presents at Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep-14-2021 .

Neutral

Lake Street Capital Markets, LLC, Lake Street C...

2021-07-30 21:59:00

Lake Street Capital Markets, LLC, Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep 14, 2021 through Sep 15, 2021.

Positive

Veracyte Revises Revenue Guidance for the Year 2021

2021-07-29 20:05:00

Veracyte revised revenue guidance for the year 2021. The company is increasing its 2021 annual total revenue guidance to a range of $200 milli...

Negative

Veracyte, Inc. Announces Retirement of James H....

2021-07-16 13:02:00

On July 13, 2021, James H. Erlinger III, Executive Vice President, General Counsel and Secretary of Veracyte, Inc. announced his retirement fr...

Negative

Veracyte, Inc. Appoints Rebecca Chambers as Chi...

2021-07-12 12:37:00

On July 12, 2021, Veracyte, Inc. announced that it appointed Rebecca Chambers, 43, as Chief Financial Officer, effective as of July 19, 2021 (...

Negative

Veracyte, Inc. Appoints Rebecca Chambers as Exe...

2021-07-12 12:30:00

Veracyte, Inc. announced the appointment of Rebecca Chambers as executive vice president and chief financial officer. Ms. Chambers, a seasoned...

Neutral

Veracyte, Inc. to Report Q2, 2021 Results on Ju...

2021-07-08 20:05:00

Veracyte, Inc. announced that they will report Q2, 2021 results After-Market on Jul 29, 2021

Neutral

Veracyte, Inc., Q2 2021 Earnings Call, Jul 29, 2021

2021-07-08 20:05:00

Veracyte, Inc., Q2 2021 Earnings Call, Jul 29, 2021

Negative

Veracyte, Inc. Announces Executive Appointments

2021-07-08 12:30:00

Veracyte, Inc. announced key appointments that further strengthen its executive team and support the company’s global expansion. Rob Brainin w...

Negative

Veracyte Announces Executive Appointments

2021-07-01 12:45:00

Veracyte announced key appointments that expand and further strengthen the company’s medical team. William A. Bulman, M.D. and Paul Kelly Mar...

Positive

Veracyte, Inc. Shows Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice

2022-06-20 12:15:00

Veracyte, Inc. announced that findings from a new meta-analysis provide real-world evidence that the Afirma Genomic Sequencing Classifier can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules and that, when the test deems a nodule as suspicious, the patient’s risk of malignancy is consistent, and higher than that reported in the test’s original clinical validation study. The findings were presented for the first time at the ENDO 2022 Annual Conference. In the new meta-analysis, researchers evaluated 13 independent studies and found that the Afirma GSC’sreal-world ability to identify benign nodules with high sensitivity and high negative predictive value for thyroid cancer was similar to the CV study results. Additionally, the meta-analysis data show that the Afirma test’s real-world performance surpasses that shown in the CV study when predicting the risk of malignancy in nodules labeled suspicious. Veracyte estimates that each year approximately 565,000 people undergo fine-needle aspiration biopsy evaluation for potentially cancerous thyroid nodules and that more than 110,000 of these patients receive indeterminate results – meaning their nodules are not clearly benign or malignant based on traditional cytopathology evaluation. Historically, most of these patients were directed to diagnostic surgery, even though70% to 80% of the time, the nodules proved to be benign. Current American Thyroid Association guidelines include molecular testing as a recommended option to achieve definitive diagnosis for nodules classified as indeterminate following FNA biopsy.

Neutral

Veracyte, Inc. Presents at ENDO 2022 Annual Conference, Jun-11-2022

2022-06-20 12:15:00

Veracyte, Inc. Presents at ENDO 2022 Annual Conference, Jun-11-2022 . Venue: Atlanta, Georgia, United States.

Positive

Veracyte, Inc. Announces the Publication of Data Reinforcing the Clinical Utility of the Decipher Prostate Genomic Classifier

2022-06-03 12:30:00

Veracyte, Inc. announced the publication of data reinforcing the clinical utility of the Decipher Prostate genomic classifier for helping to guide the timing and intensity of therapy in men experiencing prostate cancer recurrence following radical prostatectomy (RP). The findings, from an ancillary study of the prospective open-label, multicenter, randomized phase 3 SAKK 09/10 trial conducted at 28 centers in Belgium, Germany, and Switzerland, appear in Annals of Oncology. It is estimated that more than 40 percent of men with intermediate- or high-risk prostate cancer may experience a biochemical disease recurrence after RP, which is characterized by rising levels of serum prostate-specific antigen (PSA). For men who experience a rising PSA, determining the optimal timing to initiate salvage radiotherapy (SRT) and whether to add androgen deprivation therapy (ADT) to SRT is challenging. This decision is important in part because the side effects of ADT when given concurrently with SRT are often difficult for patients to manage and are associated with long-term cardiovascular impact of hormone therapy.Researchers in the Swiss Group for Clinical Cancer Research (SAKK) and collaborating cancer centers assessed the clinical outcomes and Decipher Prostate genomic risk for 226 prostate cancer patients from the SAKK 09/10 trial, which randomized patients to standard vs. dose-escalated SRT. This study involved men experiencing a rise in PSA following RP, all of whom received SRT without the addition of ADT. Patients in the Decipher Prostate analysis were followed for amedian of 6.3 years. Findings suggest that Decipher Prostate can identify the patients who are at risk of cancer progression following RP and would benefit from earlier, more intensive treatment. Patients with a high Decipher score were more than twice as likely than those with a lower Decipher score to experience biochemical and clinical progression, and to receive long-term salvage hormone therapy. Additionally, patients with high Decipher scores had markedly improved outcomes when treated with SRT when the PSA burden was still low as compared to late SRT, when PSA levels have already.

Positive

Veracyte, Inc. Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

2022-05-31 20:20:00

Veracyte, Inc. announced that new data published online in The Lancet Oncology suggest that the company's Immunoscore Immune Checkpoint (IC) assay may identify patients with metastatic colorectal cancer (mCRC) who are likely to benefit from the addition of immune checkpoint inhibitor (ICI) therapy to standard first-line treatment. The findings are from the randomized, controlled, phase II AtezoTRIBE trial, a multicenter Italian clinical study, sponsored by GONO Foundation. The vast majority of mCRC tumors (approximately 95 percent) have a proficient DNA mismatch repair (pMMR) system and are microsatellite stable. These tumors have low immunogenicity and do not derive benefit from immune checkpoint inhibitors. Previous research suggests that the FOLFOXIRI and bevacizumab combination enhances immunogenicity in pMMR mCRC. In the current study, researchers found a modest benefit of the experimental treatment regimen in this subgroup.

Neutral

Veracyte, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 02:40 PM

2022-05-27 00:00:00

Veracyte, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-13-2022 02:40 PM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Marc A. Stapley, CEO & Director, Rebecca Chambers, Executive VP & CFO.

Positive

Veracyte, Inc. Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

2022-05-26 21:05:00

Veracyte, Inc. announced new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) assay to predict which patients with metastatic non-small cell lung cancer (NSCLC) may benefit from immune checkpoint inhibitors (ICIs). The findings will be shared in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 6 at 1:15 p.m. CDT. For the study, researchers evaluated the Immunoscore IC assay in two independent cohorts totaling 265 patients who were treated with anti-PD1 or anti-PD-L1 antibodies (immune checkpoint inhibitors). The Immunoscore IC assay provided a risk score that was significantly associated with patients’ progression-free survival and overall survival. Within the two cohorts, all patients (100%) with a “high-risk” Immunoscore IC result relapsed in less than 18 months. In contrast, 34% and 33% of patients with a “low-risk” Immunoscore IC result did not relapse for a period of at least 36 months, in each cohort. Immunoscore IC is a novel assay designed to help predict a patient’s response to immune checkpoint inhibitors. The assay measures the densities of PD-L1+ and CD8+ cells, as well as the proximity among these cells on a single tissue section using imaging tools, and then produces a risk score based on a proprietary algorithm. The Immunoscore IC assay is available as a service for biopharmaceutical companies and is part of the Immunoscore family of assays. These assays measure the immune reaction in and around the tumor and help to determine drugs’ mechanisms of action and their impact on the tumor microenvironment (TME). The Immunoscore Colon Cancer test is available clinically and analyzes T lymphocyte infiltration at the tumor site to help guide treatment decisions in localized colon cancer.

Neutral

Veracyte, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 01:40 PM

2022-05-26 12:15:00

Veracyte, Inc. Presents at William Blair’s 42nd Annual Growth Stock Conference 2022, Jun-08-2022 01:40 PM. Venue: Loews Chicago Hotel, Chicago, Illinois, United States. Speakers: Marc A. Stapley, CEO & Director, Rebecca Chambers, Executive VP & CFO.

Positive

Veracyte, Inc. Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

2022-05-16 20:17:00

Veracyte, Inc. announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force (USPSTF) screening criteria. The findings were presented at the American Thoracic Society 2022 International Conference (ATS 2022), being held in San Francisco. For the study, researchers evaluated data from a subset of 291 current and former smokers with lung nodules who were part of the original clinical validation study for the Percepta Nasal Swab test. Among these individuals, 213 (73%) met USPSTF screening criteria (pack years =20, years since quit <15, age 50-80 years), while 78 (27%) did not. Researchers compared the performance of the classifier in the two patient subsets and found no statistically significant differences in the classifier’s sensitivity and specificity between the two groups. Specifically, among those who met the USPSTF criteria for lung cancer screening, the test’s sensitivity was 96% when it identified a nodule as low risk for cancer and its specificity was 94% when it identified it as high risk. Among patients who did not meet the USPSTF lung cancer screening eligibility, the test’s sensitivity was 100% when it identified nodules as low risk for cancer and its specificity was 88% when it identified them as high risk. The Percepta Nasal Swab test’s performance in classifying lung cancer risk has previously been demonstrated, and it is being made available to a limited number of sites as the company develops the clinical utility evidence to support reimbursement.

Neutral

Veracyte, Inc. Presents at American Association of Clinical Endocrinology (AACE) Annual Meeting, May-12-2022

2022-05-12 18:39:00

Veracyte, Inc. Presents at American Association of Clinical Endocrinology (AACE) Annual Meeting, May-12-2022 . Venue: San Diego, United States. Speakers: Joshua Klopper, Medical Director, Endocrinology.

Neutral

Veracyte, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-06-2022 01:15 PM

2022-05-12 12:30:00

Veracyte, Inc. Presents at The 2022 ASCO Annual Meeting, Jun-06-2022 01:15 PM. Venue: McCormick Place, Chicago, Illinois, United States. Speakers: Jérôme Galon.

Positive

Veracyte, Inc. Revises Revenue Guidance for the Full Year 2022

2022-05-03 20:05:00

Veracyte, Inc. revised revenue guidance for the full year 2022. The company is currently projecting full year 2022 total revenue of $265 million to $275 million, representing year-over-year growth of 21% to 25% compared to the prior year. This compares to prior 2022 total revenue guidance of $260 million to $275 million.

Neutral

Veracyte, Inc. Presents at American Urological Association, May-13-2022 through May-16-2022

2022-04-28 20:15:00

Veracyte, Inc. Presents at American Urological Association, May-13-2022 through May-16-2022. Venue: New Orleans, Louisiana, United States. Presentation Date(s): May-13-2022. May-15-2022.

Neutral

Veracyte, Inc., Annual General Meeting, Jun 15, 2022

2022-04-26 20:15:00

Veracyte, Inc., Annual General Meeting, Jun 15, 2022.

Neutral

Veracyte, Inc. - Shareholder/Analyst Call

2022-04-26 20:15:00

Annual General Meeting

Neutral

Veracyte, Inc. Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022

2022-04-26 20:05:00

Veracyte, Inc. Presents at American Thoracic Society 2022 International Conference, May-13-2022 through May-18-2022. Venue: San Francicso, California, United States. Presentation Date & Speakers: May-16-2022, Carla R Lamb, Lahey Hospital & Medical Center. May-17-2022, David Feller-Kopman, M.D, Lisa H Lancaster, M.D., Shaheen Islam, M.D.

Neutral

Veracyte, Inc., Q1 2022 Earnings Call, May 03, 2022

2022-04-19 12:15:00

Veracyte, Inc., Q1 2022 Earnings Call, May 03, 2022

Neutral

Veracyte, Inc. to Report Q1, 2022 Results on May 03, 2022

2022-04-19 12:15:00

Veracyte, Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022

Neutral

American Urological Association, Inc, American Urological Association, May 13, 2022 through May 16, 2022

2022-03-29 00:00:00

American Urological Association, Inc, American Urological Association, May 13, 2022 through May 16, 2022. Venue: New Orleans, Louisiana, United States.

Neutral

Endocrine Society, ENDO 2022 Annual Conference, Jun 11, 2022 through Jun 14, 2022

2022-02-28 18:25:00

Endocrine Society, ENDO 2022 Annual Conference, Jun 11, 2022 through Jun 14, 2022. Venue: Atlanta, Georgia, United States.

Neutral

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022

2022-02-08 07:31:00

The Goldman Sachs Group, Inc., Goldman Sachs 43rd Annual Global Healthcare Conference, Jun 13, 2022 through Jun 16, 2022. Venue: Terranea Resort, Rancho Palos Verdes, California, United States.

Positive

Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium

2022-01-31 13:25:00

Veracyte, Inc. announced that six abstracts highlighting new data for the company’s Decipher urologic cancer tests will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif., and virtually, February 17-19, 2022. The accepted abstracts include data from a phase 3 study evaluating the Decipher genomic classifier as a prognostic biomarker for patients diagnosed with intermediate-risk prostate cancer from their diagnostic biopsy specimen. This is the first late-stage clinical study validating the use of any gene expression classifier as a prognostic biomarker in this setting.

Neutral

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022

2022-01-25 11:00:00

William Blair & Company, L.L.C., William Blair’s 42nd Annual Growth Stock Conference 2022, Jun 06, 2022 through Jun 09, 2022. Venue: Loews Chicago Hotel, Chicago, Illinois, United States.

Positive

Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis

2021-12-14 21:05:00

Veracyte, Inc. announced the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary fibrosis (IPF). The findings, which appear online in the Annals of the American Thoracic Society (AnnalsATS), suggest that use of the test increases diagnostic accuracy, physician confidence in diagnosis, and patient referral to appropriate therapy, while also reducing invasive and potentially risky surgical lung biopsies (SLBs). Findings from the study were previously presented at the CHEST Annual Meeting 2021 in October. The company estimates that each year in the United States and Europe approximately 200,000 patients have unclear results following evaluation for suspected interstitial lung diseases (ILDs), including IPF, which is among the most common, deadly and difficult to diagnose of these lung-scarring diseases. The Envisia classifier is a highly accurate, clinically validated molecular test that detects a genomic pattern of usual interstitial pneumonia (UIP), a critical factor that can help physicians differentiate IPF from other ILDs. For the study, each survey participant received five patient cases from the BRAVE (Bronchial Sample Collection for a Novel Genomic Test) study and was asked to determine an ILD diagnosis, their confidence level in their diagnosis and the next management step. A cohort of 81 physicians initially reviewed cases without Envisia test results (pre-Envisia) and then again with the classifier results added (post-Envisia). Researchers randomly selected the patient cases from a set of 11 that all had undiagnosed ILD, a high-resolution computed tomography (HRCT) scan without a “typical” UIP pattern, and a UIP-positive Envisia test result, and had undergone multidisciplinary team discussion that resulted in a final diagnosis of IPF. Among the cohort of 81 physicians who reviewed cases both pre- and post-Envisia (a total of 155 case reviews), use of the Envisia test: Increased IPF diagnosis by an absolute difference of 39%, from 47 (30%) pre-Envisia to 107 (69%) post-Envisia, and also decreased the number of unclassifiable ILD diagnoses by an absolute difference of 10.5%, from 24 (15%) to 7 (4.5%); Increased the number of physicians saying they had a high level of confidence (>90%) in their diagnosis by an absolute difference of 36.2%, from 9 (5.8%) pre-Envisia to 65 (42%) post-Envisia; Increased the recommendation for patients to initiate antifibrotic treatment by an absolute difference of 36.4%, from 15 (10%) pre-Envisia to 72 (46.4%) post-Envisia; Decreased the recommendation for an SLB or cryobiopsy significantly decreased from 40 (26%) pre- Envisia to 26 (17%) post-Envisia.

Neutral

American Society Of Clinical Oncology, Inc., the 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022

2021-12-10 06:32:00

American Society Of Clinical Oncology, Inc., The 2022 ASCO Annual Meeting, Jun 03, 2022 through Jun 07, 2022. Venue: McCormick Place, Chicago, Illinois, United States.

Positive

Veracyte Announces New Data on Immuno-Oncology Offerings Presented At SITC 2021

2021-11-13 12:00:00

Veracyte, Inc. announced that new data from three posters were presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, highlighting the company’s immuno-oncology offerings for biopharmaceutical and academic researchers. The data demonstrate the ability of Brightplex to assess the spatial distribution of targeted immune cell subpopulations in tumors, which could potentially help clinical researchers design more effective immunotherapies in cancer treatment. Veracyte acquired the novel Brightplex technology – which combines information from multiplex immunohistochemistry (IHC) and advanced digital pathology analysis to provide a comprehensive picture of the tumor micro-environment – through its acquisition of HalioDx in August 2021. The posters include new data regarding the use of Brightplex TCE (for T Cells Exhaustion) to stratify non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors in the “Biomarker analysis” part of the PIONeeR project. This research program, promoted by the French government, is designed to better understand, predict and overcome anti-PD-1/PD-L1 resistance in advanced lung cancer patients and includes the analysis of hundreds of circulating and tumor biomarkers. The new findings on a preliminary PIONeeR patient data set suggest that one of those tests, the Brightplex TCE assay, can stratify NSCLC patients eligible for anti-PD-1/PD-L1 therapy into four Spatial Tumor-infiltrating lymphocyte (TILs) subtypes – Cold, Stroma-infiltrated, Parenchyma Hot and Hot – which may predict their outcomes. In the Hot subtype, for example, long-term progression-free survival (PFS) is observed for more than 40% of patients, regardless of PD-L1 status. In this Hot subtype, activated T-cell densities seem higher in tumors of patients with longer PFS, suggesting that immune-response evaluation with the Brightplex TCE assay could refine the stratification of patients, enriching responders to immune checkpoint inhibitor therapy.

Neutral

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022

2021-11-13 09:53:00

American Thoracic Society, Inc, American Thoracic Society 2022 International Conference, May 13, 2022 through May 18, 2022. Venue: San Francicso, California, United States.

Positive

Veracyte, Inc. Revises Earnings Guidance for the Year of 2021

2021-11-09 21:05:00

Veracyte, Inc. revised earnings guidance for the year of 2021, for the year, the company is updating its 2021 annual total revenue guidance to $210 million to $218 million, from the previous guidance range of $200 million to $208 million, with HalioDx expecting to contribute approximately $10 million. This range represents 79% to 86% total revenue growth for fiscal 2021 compared to fiscal 2020.

Positive

Veracyte, Inc. Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia

2021-11-05 12:15:00

Veracyte, Inc. announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with localized colon cancer. The new guidelines appear online in Annals of Oncology and will be highlighted at the ESMO Asia Virtual Oncology Week 2021 meeting, being held November 17-23, 2021. The Immunoscore Colon Cancer test was included in the 2020 ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Colon Cancer. The new Pan-Asian guidelines take into account ethnic differences associated with the treatment of localized colon cancer in Asian patients. They comprise the consensus opinions reached by 14 experts representing the oncological societies of Japan, China, India, Korea, Malaysia, Singapore and Taiwan.

Positive

Veracyte, Inc. Announces the Publication of New Long-Term Clinical Utility Data Showing

2021-11-03 12:15:00

Veracyte, Inc. announced the publication of new long-term clinical utility data showing that the company’s Afirma Genomic Sequencing Classifier (GSC) helped reduce unnecessary surgeries in patients with indeterminate thyroid nodule cytology, as compared to the use of no molecular testing. The peer-reviewed paper appears online in The Journal of the Endocrine Society. Veracyte estimates that each year approximately 565,000 people with thyroid nodules undergo fine-needle aspiration (FNA) biopsies to assess potentially cancerous nodules. Up to 30% of these patients receive indeterminate results – meaning their nodules are not clearly benign or malignant based on traditional cytopathology evaluation. Historically, most of these patients were directed to diagnostic surgery, even though 70% to 80% of the time the nodules proved to be benign. The Afirma GSC helps physicians identify patients with benign thyroid nodules from among those with indeterminate FNA results, so that they may avoid unnecessary thyroid surgery. Current American Thyroid Association guidelines include molecular testing as a recommended option to achieve definitive diagnosis for nodules classified as indeterminate following FNA biopsy. In the current study, researchers at the University of Nebraska Medical Center (UNMC) and the VA Nebraska-Western Iowa Health System retrospectively analyzed 468 cytologically indeterminate thyroid nodules from January 2013 to December 2019 to assess and compare how use of the Afirma GSC (n=124) and the original Afirma Gene Expression Classifier (GEC; n=71) impacted patient care. Use of these tests was also compared to nodules that did not undergo molecular testing (n=273). They found that the Afirma GSC identified 30 percent more nodules as benign, compared to the GEC (60% vs. 46%, respectively) and that use of the Afirma GSC resulted in 41% percent fewer surgeries, compared to patients with no molecular testing (40% vs. 68%, respectively). Additionally, when surgery was performed, patients deemed “suspicious for cancer” by the Afirma.

Neutral

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Positive

Veracyte, Inc. Announces New Data Demonstrate Clinical Utility of its Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery

2021-10-26 13:25:00

Veracyte, Inc. announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the timing and intensity of treatment in men experiencing prostate cancer progression following radical prostatectomy. The data, from a randomized, phase 3 trial conducted at 24 centers in Belgium, Germany, and Switzerland (SAKK 09/10), were presented on October 26, 2021 at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2021 (abstract #94). Following radical prostatectomy, physicians typically monitor prostate cancer patients’ prostate-specific antigen (PSA) to identify biochemical recurrence. For those men who experience a subsequent rise in PSA, determining the optimal timing to initiate treatment and whether to add androgen deprivation therapy (ADT) to radiotherapy is challenging. Conventional clinical measures such as PSA and pathological findings following surgery are often insufficient to predict which patients will experience favorable oncologic outcomes with radiotherapy alone, and which will have disease that continues to progress. To determine whether the Decipher Prostate genomic classifier could help identify those patients who would benefit from earlier intervention with radiotherapy or the addition of ADT to radiotherapy in this setting, researchers in the Swiss Group for Clinical Cancer Research (SAKK) and collaborating cancer centers assessed the outcomes and Decipher Prostate genomic risk for 226 prostate cancer patients from the SAKK 09/10 phase 3 randomized clinical trial. This study involved men experiencing a rise in PSA following radical prostatectomy, all of whom received radiotherapy without the addition of ADT. Patients in the Decipher Prostate analysis were followed for a median of 6.3 years. The data shared at ASTRO on October 26, 2021 show that men with disease classified as Decipher high-risk were more than twice as likely as those whose disease was classified as Decipher low/intermediate-risk to experience biochemical and clinical progression with radiotherapy alone. Additionally, Decipher high-risk patients with PSA levels above 0.5 ng/mL who received radiotherapy alone had a nearly 90% risk of cancer recurrence in the five years following treatment.

Positive

Veracyte, Inc. Announces That New Data Being Presented At the American Society for Radiation Oncology 2021 Annual Meeting

2021-10-25 14:30:00

Veracyte, Inc. announced that new data being presented at the American Society for Radiation Oncology 2021 Annual Meeting suggest the company’s Decipher Prostate genomic classifier identifies patients with clinically high-risk prostate cancer who may require treatment intensification beyond standard-of-care therapy. The findings, from a pre-specified analysis of biopsy samples taken from prostate cancer patients with clinically high-risk disease who were enrolled in multiple phase 3, prospective, randomized studies, show that Decipher Prostate test scores are independently associated with distant metastases, prostate cancer-specific mortality and overall survival in this patient population. After a median follow up of 11 years, men with disease classified as Decipher high-risk experienced substantially less favorable outcomes compared to men with disease classified as Decipher low-risk. For the analysis, Dr. Nguyen and colleagues obtained Decipher Prostate scores for 265 biopsy samples from the NRG/RTOG 9202, 9413 and 9902 phase 3 randomized trials. After multi-variable analyses adjusting for age, prostate-specific antigen (PSA) levels, Gleason score, cT-stage, trial and randomized treatment arm, researchers found that Decipher Prostate scores were independently associated with distant metastases, prostate cancer-specific mortality (1.27) and overall survival (1.12). The cumulative incidence of DM at 10 years was 26%, 15% and 6% for men who were Decipher high-risk, intermediate-risk and low-risk, respectively. Among the subset of patients with a Decipher Prostate score >0.85 (within the “high-risk” range of 0.6-1.0), DM was 29% at 5 years and 41% at 10 years. Treatment intensification for men with clinically high-risk prostate cancer and Decipher scores above 0.85 is being studied in the currently enrolling, prospective, phase 3 randomized trial NRG-GU009 (PREDICT-RT), which also studies treatment de-intensification by halving the duration of hormonal therapy in men with Decipher scores 0.85 or less. Along with PREDICT-RT, the Decipher Prostate genomic classifier is currently being investigated in seven National Cancer Institute-sponsored, phase 3, prospective, randomized controlled clinical trials; 13 phase 2/3 prospective trials; and more than 20 retrospective studies of phase 3 randomized controlled trials. Many of these trials require Decipher Prostate testing for study inclusion.

Positive

New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

2021-10-14 12:35:00

Veracyte, Inc. announced that new data further validating the clinical utility of the company’s Decipher Prostate genomic test will be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2021 taking place October 24-27, 2021, in Chicago. In two, separate oral presentations, investigators will share findings from studies that assessed the Decipher Prostate test in multiple, large Phase 3 randomized trials. The studies evaluated the test’s utility in patients with newly diagnosed, clinically high-risk prostate cancer receiving definitive radiotherapy as well as among patients experiencing biochemical disease progression following radical prostatectomy.

Positive

Veracyte, Inc. Announces the Publication of New Data Demonstrating That the Company’s Decipher Bladder Genomic Classifier

2021-10-13 12:55:00

Veracyte, Inc. announced the publication of new data demonstrating that the company’s Decipher Bladder genomic classifier accurately identifies bladder tumors that are most likely to respond to chemotherapy prior to radical cystectomy. These findings could ultimately help physicians optimize treatment planning for their patients with bladder cancer based on their tumor subtype biology. The peer-reviewed paper appears online in The Journal of Urology. Patients diagnosed with non-metastatic muscle-invasive bladder cancer (MIBC) often undergo neoadjuvant chemotherapy (NAC) prior to standard-of-care radical cystectomy, even though the absolute survival benefit associated with the addition of NAC to radical cystectomy is 5-10%. Until recently, there was no reliable way to determine which MIBC tumors would – or would not – respond to chemotherapy. Molecular subtyping with the Decipher Bladder genomic classifier has shown that biological differences in MIBC are strongly associated with chemotherapy response. In this multicenter retrospective study, scientists evaluated the use of the Decipher Bladder genomic classifier in a cohort of 601 patients. After three years, patients with classifier-identified luminal tumors (37% of the study population) experienced no additional benefit to overall survival (OS) from receiving NAC prior to radical cystectomy (63% OS with NAC and 65% OS without). However, those patients whose tumors were classified as non-luminal (63% of the study population) experienced a significant benefit from the addition of NAC, with 10% greater overall survival after three years as compared to patients who were treated with cystectomy alone (71% vs. 61%). The Decipher Bladder test is supported by multiple peer-reviewed clinical studies demonstrating its ability to identify which patients have a higher risk of upstaging to non-organ confined disease at surgery and which patients may benefit the most from neoadjuvant therapy. The test also can be used to identify neuroendocrine-like and immune-infiltrated subtypes, which may have implications for future therapeutic strategies. In June 2021, Veracyte announced that Decipher Bladder had become the first molecular subtyping test to gain Medicare coverage to inform treatment for individuals with bladder cancer.

Neutral

Veracyte, Inc. to Report Q3, 2021 Results on Nov 09, 2021

2021-10-12 20:05:00

Veracyte, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Neutral

Veracyte, Inc., Q3 2021 Earnings Call, Nov 09, 2021

2021-10-12 20:05:00

Veracyte, Inc., Q3 2021 Earnings Call, Nov 09, 2021

Positive

New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

2021-10-11 20:41:00

Veracyte, Inc. announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic pulmonary fibrosis (IPF) by increasing diagnostic accuracy, physician confidence in diagnosis, and patient referral to appropriate therapy. The data, from a prospective, randomized decision-impact survey involving more than 100 pulmonologists, will be shared October 18 in an oral presentation at the American College of Chest Physicians (CHEST) Annual Meeting 2021 (Abstract #40063). Veracyte estimates that each year in the United States and Europe approximately 200,000 patients have unclear results following evaluation for suspected interstitial lung diseases (ILDs), including IPF, which is among the most common, deadly and difficult to diagnose of these lung-scarring diseases. The Envisia Genomic Classifier is a highly accurate, clinically validated molecular test that detects a genomic pattern of usual interstitial pneumonia (UIP), a critical factor that can help physicians differentiate IPF from other ILDs.

Positive

Veracyte, Inc. Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment

2021-10-11 12:15:00

Veracyte, Inc. announced that new expanded clinical validation data reinforce the ability of the company’s noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules. The findings also show that the test delivers strong clinical performance across different nodule sizes and cancer stages in current or former smokers, and for patients who have already had other cancers. The new data underscore the Percepta Nasal Swab test’s ability to help physicians more accurately, quickly and confidently determine which patients with lung nodules found on computerized tomography (CT) scans may avoid unnecessary invasive procedures and which should proceed to diagnostic work-ups and obtain treatment if necessary. The findings will be shared in an oral presentation at the 2021 American College of Chest Physicians (CHEST) Annual Meeting, which is being held virtually October 17, 2021 to October 20, 2021. The company also announced it has begun making the Percepta Nasal Swab test available to a limited number of clinical sites as it builds the clinical utility data to support reimbursement. The Percepta Nasal Swab test’s robust performance in classifying lung cancer risk was previously demonstrated in a blinded, independent validation set of 249 patients from multiple cohorts comprising prospectively collected nasal samples. All patients were current or former smokers undergoing evaluation for lung nodules found on CT scans. Patients were followed for up to one year or until physicians made a final, adjudicated diagnosis. The new expanded data being presented at CHEST 2021 meeting include 63 additional patients with prior (non-lung) cancers who were part of a planned secondary endpoint analysis. In the expanded cohort of 312 patients, when the Percepta Nasal Swab test identified patients as low risk, its sensitivity was 97%, providing a negative predictive value (NPV) of 98% in a population with the 25% cancer prevalence that would be expected in a broad cohort with suspicious lung nodules. This NPV would assist physicians in avoiding unnecessary invasive procedures in these patients with a very small likelihood of missing a cancer. When the test identified patients as high risk, its specificity was 92%, for a positive predictive value (PPV) of 70% at a malignancy rate of 25%. This PPV would assist physicians in directing these patients to further procedures so they could obtain an accurate diagnosis and speed time to treatment if necessary. Patients in the moderate risk group could be managed according to current clinical guidelines. In a sub-analysis of the expanded validation set, researchers found that the Percepta Nasal Swab test’s performance is strong across different nodule sizes, with the test identifying 67% of cancers in nodules below 8 mm as moderate risk, while labeling 100% of malignant nodules greater than or equal to 8 mm as high or moderate risk. Performance was also consistent across all stages of non-small cell lung cancer (NSCLC), with 100% of NSCLC Stage II or greater cancers labeled as moderate or high risk. Also at the CHEST meeting, real-world data will be presented demonstrating that the Percepta Genomic Sequencing Classifier (GSC) can help reduce unnecessary surgeries and guide next steps in lung cancer evaluation for patients with suspicious lung nodules whose bronchoscopy results were inconclusive. In one retrospective clinical utility study, researchers from the Medical College of Wisconsin found that the Percepta GSC reclassified one-third of lung nodules with indeterminate bronchoscopy results as either low risk or high risk. Similarly, researchers from AnMed Health Medical Center in Anderson, South Carolina, found that the Percepta GSC enabled more than half of patients’ indeterminate lung nodules to be reclassified and, among those moved to a low risk category, there was a significant reduction in the rate of invasive follow-up procedures. The Percepta Nasal Swab test and GSC use advanced genomic technology to detect smoking-related damage associated with lung cancer in the respiratory tract of current or former smokers. Both tests are part of the company’s comprehensive lung cancer portfolio, which aims to transform care at every step of the patient journey. Collectively, the company’s tests are leveraging cutting-edge genomic science and technology to provide answers and insights that enable physicians and patients to make best, fast and more confident care decisions. The company’s lung cancer portfolio also includes the in-development Percepta Genomic Atlas, which is intended to detect gene alterations that may inform lung cancer treatment decisions, using the same small biopsy that was collected for diagnosis.

Positive

Veracyte, Inc Announces New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy

2021-09-14 20:05:00

Veracyte, Inc. announced that its Decipher® Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer. The new guidelines specifically recommend Decipher Prostate RP after radical prostatectomy and that men with high-risk scores (>0.6) should be strongly considered for salvage radiotherapy with the addition of concurrent hormone therapy, when early radiation therapy is missed. The new NCCN recommendations are based on results of the NRG Oncology Phase 3 randomized controlled trial, RTOG 96-01. This study, which followed patients for a median of 12 years, demonstrated that Decipher risk results were associated with hormone therapy benefit, with Decipher high-risk men receiving greater absolute benefit from hormone therapy compared to Decipher low-risk men. In the subset of patients who received hormone therapy in addition to early salvage radiotherapy, Decipher high-risk men experienced improvements in distant metastasis, prostate cancer-specific mortality and overall survival, while Decipher low-risk men had good oncologic outcomes without hormone therapy. The Decipher Prostate genomic classifier is currently being investigated in seven National Cancer Institute-sponsored, Phase 3, prospective, randomized controlled clinical trials; 13 Phase 2/3 prospective trials; and more than 20 retrospective studies of Phase 3 randomized controlled trials. Many of these trials require Decipher Prostate testing for study inclusion.

Negative

Veracyte, Inc. Announces Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology

2021-09-01 12:35:00

Veracyte, Inc. announced that it has appointed Joshua Klopper, M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte, reporting to Richard T. Kloos, M.D., Veracyte’s executive medical director. Dr. Klopper most recently served as regional service chief of the Colorado Permanente Medical Group (CPMG) of Kaiser Permanente. Prior to his work at CPMG, Dr. Klopper was a full-time faculty member in the Division of Endocrinology at the University of Colorado School of Medicine, where he specialized in thyroid nodule and thyroid cancer evaluation and management. Dr. Klopper was the co-director of the Endocrine Society Introductory Hands-On Thyroid Ultrasound Workshop for five years and has served on the American Thyroid Association board of directors. Dr. Klopper graduated from the Emory University School of Medicine. He completed his internship and residency in internal medicine at the University of Colorado Health Sciences Center (UCHSC). He subsequently completed both a postdoctoral research fellowship in the Endocrinology Division of UCHSC and an endocrinology fellowship.

Neutral

Veracyte, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 03:30 PM

2021-08-31 12:15:00

Veracyte, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 03:30 PM. Venue: New Windsor, United States. Speakers: Marc A. Stapley, CEO & Director, Rebecca Chambers, EVP & CFO.

Neutral

Veracyte, Inc. has closed its Shelf Registration dated August 04, 2021 in the amount of $147.088842 million.

2021-08-04 00:00:00

Veracyte, Inc. has closed its Shelf Registration dated August 04, 2021 in the amount of $147.088842 million. Security Name: Common Stock Securities Offered: 3,347,493

Positive

Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of HalioDx SAS from M.I.3. SA, PSIM fund managed by Bpifrance Investissement SAS, Sham Innovation Santé advised by Turenne Capital, Bpifrance Investissement SAS, Sofipaca SCR, Amundi Private Equity Funds S.A., Quest for Growth Belgium (ENXTBR:QFG) managed by Capricorn Venture Partners and others.

2021-08-02 00:00:00

Veracyte, Inc. (NasdaqGM:VCYT) entered into a memorandum of understanding to acquire HalioDx SAS from M.I.3. SA, PSIM fund managed by Bpifrance Investissement SAS, Sham Innovation Santé advised by Turenne Capital, Bpifrance Investissement SAS, Sofipaca SCR, Amundi Private Equity Funds S.A., Quest for Growth Belgium (ENXTBR:QFG) managed by Capricorn Venture Partners and others for approximately €260 million on June 1, 2021. Veracyte, Inc. (NasdaqGM:VCYT) entered into a Securities Purchase and Contribution Agreement to acquire HalioDx SAS from M.I.3. SA, PSIM fund managed by Bpifrance Investissement SAS, Sham Innovation Santé advised by Turenne Capital, Bpifrance Investissement SAS, Sofipaca SCR, Amundi Private Equity Funds S.A., Quest for Growth Belgium (ENXTBR:QFG) managed by Capricorn Venture Partners and others on July 13, 2021. At closing, Veracyte will pay approximately €260 million in total consideration to HalioDx security holders, consisting of approximately €147 million in cash and up to approximately €113 million in stock. As per the agreement, 10% of the total consideration to be paid into escrow and 20% of the consideration to be paid to certain founders of HalioDx to be subject to a holdback provision. The transaction is subject to customary purchase price adjustments. HalioDx will become a subsidiary of Veracyte. HalioDx’s operations and laboratories will remain in Marseille, France and Richmond, Virginia. Veracyte expects that the shareholders of HalioDx will enter into a definitive purchase agreement with Veracyte for the purchase and sale of HalioDx. The transaction is subject to the satisfaction of customary closing conditions, including foreign investment approval in France. The transaction has been unanimously approved by Veracyte’s board of directors and is fully supported by the HalioDx board of directors. The transaction is expected to close in the third fiscal quarter of 2021. Veracyte expects the acquisition of HalioDx to be accretive to its revenue growth in 2021 and to expand the near-term addressable markets for Veracyte’s current and pipeline tests. Veracyte also expects the transaction to be strategically accretive to its gross margins once it transitions manufacturing of test kits to HalioDx for use on the nCounter Analysis System. Goldman Sachs & Co. LLC is serving as financial advisor to Veracyte, and Ken Myers, Lynda Twomey, Stephen Gillespie, Ali Kongats, Mark Jansen, Doug Cogen, Jake Handy, Elizabeth Gartland, Jim Koenig, Brent Hoard, Matthew Cantor, Liza Morgan, Matthew Damm and Sarah Borchers of Fenwick & West LLP and Olivier du Mottay, Mayssa Sader, Delphine Van Damme. Evelyne Van Keymeulen, Myria Saarinen, Charles-Antoine Guelluy, Jean-Luc Juhan, Matthias Rubner, Celia Gallo of Latham & Watkins LLP are serving as Veracyte’s legal advisors in the United States and France, respectively. Hervé Letréguilly, Guillaume Isautier, Michael Dorf, Jordan Altman, Doreen E. Lilienfeld, Larry Crouch, Mehran Massih, Jay M. Singer and James Webber of Shearman & Sterling LLP is serving as legal advisors to HalioDx. Veracyte, Inc. (NasdaqGM:VCYT) completed the acquisition of HalioDx SAS from M.I.3. SA, PSIM fund managed by Bpifrance Investissement SAS, Sham Innovation Santé advised by Turenne Capital, Bpifrance Investissement SAS, Sofipaca SCR, Amundi Private Equity Funds S.A., Quest for Growth Belgium (ENXTBR:QFG) managed by Capricorn Venture Partners and others on August 2, 2021.

Neutral

Veracyte, Inc. Presents at Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep-14-2021

2021-07-31 04:07:00

Veracyte, Inc. Presents at Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep-14-2021 .

Neutral

Lake Street Capital Markets, LLC, Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep 14, 2021 through Sep 15, 2021

2021-07-30 21:59:00

Lake Street Capital Markets, LLC, Lake Street Capital Markets 5th Annual Best Ideas Growth Conference, Sep 14, 2021 through Sep 15, 2021.

Positive

Veracyte Revises Revenue Guidance for the Year 2021

2021-07-29 20:05:00

Veracyte revised revenue guidance for the year 2021. The company is increasing its 2021 annual total revenue guidance to a range of $200 million to $208 million fromits previous guidance range of $190 million to $200 million. This range represents 69% to 76% total revenue growth for fiscal 2021 compared to fiscal 2020, and increased from Veracyte’s prior estimate of 61% to 69% total revenue growth.

Negative

Veracyte, Inc. Announces Retirement of James H. Erlinger III as Executive Vice President, General Counsel and Secretary, Effective July 31, 2021

2021-07-16 13:02:00

On July 13, 2021, James H. Erlinger III, Executive Vice President, General Counsel and Secretary of Veracyte, Inc. announced his retirement from the company, effective as of July 31, 2021.

Negative

Veracyte, Inc. Appoints Rebecca Chambers as Chief Financial Officer, Effective as of July 19, 2021

2021-07-12 12:37:00

On July 12, 2021, Veracyte, Inc. announced that it appointed Rebecca Chambers, 43, as Chief Financial Officer, effective as of July 19, 2021 (the “Appointment Date”). Prior to her appointment, Ms. Chambers served as Chief Financial Officer of Outset Medical, Inc. from June 2019 to July 2021. Prior to that, Ms. Chambers served in a number of roles at Illumina, Inc. including as the Vice President, Financial Planning and Analysis from July 2017 to May 2019, as Vice President, Investor Relations and Treasury from April 2015 to June 2017, and as Senior Director, Investor Relations from October 2012 to April 2015. Ms. Chambers also currently serves on the board of Inari Medical, Inc. In connection with Ms. Chambers’ appointment, on July 12, 2021, the Company also announced that Jane Alley, Acting Chief Financial Officer, would be resigning from her position as Acting Chief Financial Officer, effective as of July 19, 2021. Ms. Alley will continue to serve as the Company’s Vice President, Corporate Controller and Principal Accounting Officer.

Negative

Veracyte, Inc. Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer

2021-07-12 12:30:00

Veracyte, Inc. announced the appointment of Rebecca Chambers as executive vice president and chief financial officer. Ms. Chambers, a seasoned financial executive with a track record for scaling high-growth healthcare businesses, will join the company July 19, reporting to Marc Stapley, Veracyte’s chief executive officer. Ms. Chambers has extensive healthcare leadership experience, most recently serving as chief financial officer for Outset Medical focused on reducing the cost and complexity of dialysis.

Neutral

Veracyte, Inc. to Report Q2, 2021 Results on Jul 29, 2021

2021-07-08 20:05:00

Veracyte, Inc. announced that they will report Q2, 2021 results After-Market on Jul 29, 2021

Neutral

Veracyte, Inc., Q2 2021 Earnings Call, Jul 29, 2021

2021-07-08 20:05:00

Veracyte, Inc., Q2 2021 Earnings Call, Jul 29, 2021

Negative

Veracyte, Inc. Announces Executive Appointments

2021-07-08 12:30:00

Veracyte, Inc. announced key appointments that further strengthen its executive team and support the company’s global expansion. Rob Brainin will join the company as executive vice president and chief business officer and Bill Zondler has been appointed senior vice president and chief information officer. Both executives will report to Marc Stapley, the company’s chief executive officer. Rob Brainin brings more than 20 years of executive experience in life sciences and health care. He most recently served as chief executive officer of Genuity Science. Prior to that, he served as vice president and general manager of the Life Sciences and Applied Genomics Business at Illumina, Inc. and, before that, was vice president and general manager of the Enterprise Genomics Solutions business of Thermo Fisher Scientific, Inc. Brainin is a member of the board of directors of Champions Oncology and the Children’s Tumor Foundation. Bill Zondler’s career spans more than 25 years in information technology, including over 20 years in clinical laboratories and the pharmaceutical, medical device, life sciences and biotechnology industries. Prior to joining the company, he was the chief information officer at Biotheranostics, Inc. In this role, Zondler led the company’s digitization initiatives and advanced their cybersecurity processes. Prior to Biotheranostics, he was the full-time consulting CIO at Axovant Sciences, Inc. Previously, Zondler was CIO at Millenium Health, LLC.

Negative

Veracyte Announces Executive Appointments

2021-07-01 12:45:00

Veracyte announced key appointments that expand and further strengthen the company’s medical team. William A. Bulman, M.D. and Paul Kelly Marcom, M.D, have joined the company as medical director for Lung Cancer and medical director for Breast Cancer, respectively. Both physician executives report to Richard T. Kloos, M.D., Veracyte’s executive medical director. Dr. Bulman most recently served as associate professor of Medicine at Columbia University and the director of Interventional Bronchoscopy at New York Presbyterian Hospital. Dr. Marcom has over 30 years of experience in oncology, mostly dedicated to treating breast cancer. He joins Veracyte from Duke University Medical Center, where he was disease group leader for the Duke Cancer Institute’s multidisciplinary Breast Cancer Disease Group and a tenured professor of Medicine.

Fundamental Summary

Veracyte's financial reports for Q1 showed some underwhelming results. Their negative growth, and value factors indicate that the company is finding it increasingly difficult to produce impressive numbers. These results indicate a weak growth potential for Veracyte's stock's price moving forward. As such, Veracyte received an overall score of 59 and a UNDERPERFORM recommendation.

Veracyte reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 8.82 million compared to USD 0.566 million a year ago. Revenue was USD 67.78 million compared to USD 36.7 million a year ago. Net loss was USD 14.46 million compared to USD 41.87 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.66 a year ago.

Business Description

Veracyte operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte in March 2008. Veracyte was incorporated in 2006 and is headquartered in South San Francisco, California.

Sector Overview

Veracyte is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Veracyte's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 1,173.6 -1.2% 68
Liabilities 88.4 -3.2% 64
Price to Book 1.1 -58.1% 51
Cash & Equivalents 163.6 -5.5% 66
Equity 1,085.2 -1.0% 54
EBITDA -34.7 -1.1% 63
Total Revenues 250.6 14.2% 45
Parameter Value Change Score
Return on Equity -4.7 53.0% 57
Net Cashflow -160.4 8.8% 90
Capital Expenditure -6.6 -23.4% 46
Asset Turnover 0.2 -14.6% 46
Free Cashflow -0.1 82.8% 95

* All values are TTM

The below chart reflects Veracyte's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Veracyte's peer average final assessment score stands on 63.0, Veracyte's score is 59.

  •  VCYT
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 9 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 10 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 11 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 12 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 13 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 15 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Veracyte's stock is now priced above its 50-day, but below its 5-day and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a positive setup in the medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Veracyte's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.

Bearish 57
Close Price 19.83
52W Low 15.45
52W High 53.79
5D MA 20.82
50D MA 18.93
200D MA 32.44
MACD 0.48
RSI 50.54
STOCH 57.08

Balance Sheet Analysis

Veracyte's recently published balance sheet conveys disappointing growth, particularly with respect to Book Value Factors and Equity metrics. Veracyte's price to book ratio (P/B) was reported as 1.1 and represents -58.1% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. Their book value factor metrics are even more concerning when compared to their peers. Therefore, their book value factors earned a score of 51. Also, Veracyte reported weak equity changes momentum this period. At filing, equity was reported as 1085.2, representing -1.0% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Its equity movement component, therefore, received a grade of 54. That said, one metric, Assets, stood out as strongly positive. The company's assets section could set high expectations for Veracyte's future attractiveness, as they went to 1173.6, which is a -1.2% change from the last period. These results, specifically in contrast to their industry peers' performance, should support an upswing in the company's stock price. The company's asset component, therefore, received a grade of 68. The company's balance sheet, Therefore, earned a score of 57.

Parameter Value Change Score
Assets 1,173.6 -1.2% 68
Liabilities 88.4 -3.2% 64
Price to Book 1.1 -58.1% 51
Cash & Equivalents 163.6 -5.5% 66
Equity 1,085.2 -1.0% 54
* All values are TTM

The below chart describes Veracyte's performance as reflected on its balance sheet with respect to its peers. While Veracyte received a balance sheet score of 57, the average of its peers stands on 62.0.

  •  VCYT
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 9 1
CareDx, Inc 1.2B 54 67 52 39 51 52 10 1
MannKind Corporation 957.2M 79 59 50 40 64 57 11 1
Merus N.V. 941.6M 59 68 50 83 81 70 12 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 14 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 15 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Veracyte's income statement factors had several troubling metrics this period. Veracyte management did an underwhelming job managing revenue efficiency this past period. Veracyte's revenue efficiency is 250.6 according to the metrics in the current filing, which represents a 14.2% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency, specifically in contrast to their industry peers', isn't encouraging. As a result, their revenue efficiency earned a score of 45. Also, Veracyte's reported return on equity (ROE) ratio was -4.7, representing a change of 53.0%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. These numbers show that management has been unsuccessful in fostering appropriate growth related to return on assets and return on equity momentum relative to their peers. Therefore, their return factors component earned a score of 57. However, one encouraging metric, EBITDA, stood out. Veracyte's management did a remarkable job this period managing its EBITDA. In terms of the raw numbers, EBITDA was reported as -34.7, which represents a -1.1% change from the last period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. Therefore, its EBITDA component earned a score of 63. Therefore, it received a cautionary score of 55.

Parameter Value Change Score
EBITDA -34.7 -1.1% 63
Total Revenues 250.6 14.2% 45
Return on Equity -4.7 53.0% 57
* All values are TTM

The below chart describes Veracyte's performance as reflected on its income statement with respect to its peers. While Veracyte received a income statement score of 55 , the average of its peers stands on 66.0.

  •  VCYT
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 9 1
CareDx, Inc 1.2B 61 44 82 50 10 1
MannKind Corporation 957.2M 95 48 56 61 11 1
Merus N.V. 941.6M 48 60 59 54 12 1
Amarin Corporation plc 734.5M 95 44 82 63 13 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 15 1
Radius Health, Inc. 499.8M 94 71 68 82 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Veracyte appears likely to maintain its strong cash flow metrics and momentum going forward. Free cash flow numbers published by Veracyte were -0.1, which was a 82.8% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. Consequently, their free cash flow movement received a grade of 95. Also, Veracyte presents exciting net cash flow numbers for its recent financial release, illustrated by a net cash flow of -160.4, which is a change of 8.8% from the last filing. Their net cash flow metrics are especially remarkable relative to their peers. The company's net cash flow, therefore, received a grade of 90. At the same time, one critical cash flow metric, Capital Expenditure, was notably weak. Veracyte's published capital expenditures (CapEx) numbers were discouraging and reflected management's unbalanced growth strategy. Veracyte recorded CapEx of -6.6, which represents a -23.4% change from the previous report. They appears to be headed in the wrong direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their CapEx movement received a grade of 46. Therefore, we scored its cash flow a 82.

Parameter Value Change Score
Net Cashflow -160.4 8.8% 90
Capital Expenditure -6.6 -23.4% 46
Asset Turnover 0.2 -14.6% 46
Free Cashflow -0.1 82.8% 95
* All values are TTM

The below chart describes Veracyte's performance as reflected on its cash flow with respect to its peers. While Veracyte received a cash flow score of 82, the average of its peers stands on 71.0.

  •  VCYT
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 9 1
CareDx, Inc 1.2B 98 84 40 50 86 10 1
MannKind Corporation 957.2M 77 56 43 37 66 11 1
Merus N.V. 941.6M 70 71 74 53 71 12 1
Amarin Corporation plc 734.5M 52 40 74 55 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 14 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 15 1
Radius Health, Inc. 499.8M 64 40 37 56 57 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.